University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Talmadge King, M.D.

Pulmonologist

Dr. Talmadge E. King, Jr. is chair of the Department of Medicine at the University of California, San Francisco where he oversees a department of 1,372 doctors and scientists and more than 800 support staff. His focus in patient care is interstitial lung diseases, in particular idiopathic pulmonary fibrosis, sarcoidosis, connective tissue disease, hypersensitivity pneumonitis, drug-induced lung fibrosis and other rare diffuse lung disorders. King's research interests include pathogenesis, diagnosis and management of inflammatory and immunologic lung disease. He has co-authored eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King earned a medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga., and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver. He is a member of the Association of American Physicians, American Clinical and Climatological Association and Fleischner Society and is a fellow of the American College of Physicians and the American College of Chest Physicians. He holds the Julius R. Krevans Distinguished Professorship in Internal Medicine and won the 2007 Trudeau Medal, the highest honor of the American Lung Association and American Thoracic Society.

Clinics

Interstitial Lung Disease Program
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143
Phone: (415) 353-2577
Fax: (415) 353-2568

Hours: Friday
8 a.m. – noon

Conditions & Treatments

More about Talmadge King

Education

Harvard School of Medicine 1974

Residencies

Emory University Affiliated Hospitals, Internal Medicine 1977

Fellowships

University of Colorado Medical Center, Pulmonary/Critical Care 1979

Selected Research and Publications

  1. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15; 188(6):733-48.
  2. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen ML, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013 Aug; 144(2):586-92.
  3. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-40.
  4. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1; 187(11):1272.
  5. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep; 42(3):750-7.
  6. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013 Feb; 107(2):249-55.
  7. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15; 186(4):314-24.
  8. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.
  9. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.
  10. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
  11. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11.
  12. King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Clin Chest Med. 2012 Mar; 33(1):xiii.
  13. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE, Kim DS, Collard HR. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):352-8.
  14. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1382-9.
  15. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15; 184(4):459-66.
  16. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3; 378(9807):1949-61.
  17. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1390-4.
  18. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21; 377(9779):1760-9.
  19. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1; 184(1):92-9.
  20. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.